TG Therapeutics Inc

+0.26 (+1.69%)

TG Therapeutics Announces FDA Acceptance Of Application For Ublituximab As A Treatment For Multiple Sclerosis

Published: 12/14/2021 12:44 GMT
TG Therapeutics Inc (TGTX) - Tg Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab As a Treatment for Patients With Relapsing Forms of Multiple Sclerosis.
Tg Therapeutics Inc - Prescription Drug User Fee Act (pdufa) Goal Date of September 28, 2022.
Tg Therapeutics Inc - FDA Also Notified Company That It is Not Currently Planning to Hold an Advisory Committee Meeting to Discuss This Application.